Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Search Results - jean bennett

4 Results Sort By:
Gene therapy for achromatopsia
Problem: There currently is no cure for Achromatopsia which affects up to 1: 50,000 patients in the US. Solution: Dr. Jean Bennett, MD, PhD, Kirby Professor of Ophthalmology at the University of Pennsylvania’s Perelman School of Medicine, one of the first investigators to develop a gene therapy for a rare inherited form of retinal blindness...
Published: 4/1/2020   |   Inventor(s): Jean Bennett, Jeannette Bennicelli, Junwei Sun
Keywords(s):  
Category(s): Therapeutics & Vaccines
Virtual reality for low vision patients
Problem: Low vision is a significant public health problem affecting more than 3.5 million people in the US alone compromising an individuals’ sense of independence, ability to carry out daily life activities, and safety. Without retinal input, the downstream visual pathways also deteriorate. Thus, enhancement of the remaining visual function...
Published: 4/1/2020   |   Inventor(s): Jean Bennett, Tomas Aleman, Michael Stauffer, Mikhail Lipin, Manzar Ashtari, Ranjoo Prasad
Keywords(s):  
Category(s): Medical Devices, Digital Health, Software & Data & Algorithms & Apps
Gene therapy for optic neuropathy
Problem: Optic neuritis is a condition commonly observed in MS patients that leads to temporary or permanent visual decline following demyelination of the optic nerve and loss of retinal ganglion cells. Current therapies for MS and ON include immunosuppressive agents that mitigate the inflammatory component of disease. Unfortunately, these treatments...
Published: 4/1/2020   |   Inventor(s): Kenneth Shindler, Devin McDougald, Junwei Sun, Jean Bennett
Keywords(s):  
Category(s): Therapeutics & Vaccines
Enhanced gene transfer for retinal therapies
Technology Overview: While Adeno-Associated Viruses (AAVs) shows great promise in gene therapy applications for the treatment of inherited and acquired retinal diseases, a significant challenge to date has been the limitation of AAV vectors to transduce non-permissive retinal cells and to express in a single cell type. The inventors have generated...
Published: 3/20/2020   |   Inventor(s): Jean Bennett
Keywords(s):  
Category(s): Therapeutics & Vaccines